会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • Over-the needle peel-away sheath catheter introducer
    • 超过针剥离鞘导管引导器
    • US20060041230A1
    • 2006-02-23
    • US10920064
    • 2004-08-17
    • Jeremy Davis
    • Jeremy Davis
    • A61M5/178
    • A61M25/0668A61M25/0009B29C45/0055B29C45/14344B29C45/261B29L2031/7542
    • An over-the-needle peel-away sheath catheter introducer for receiving the distal end of a catheter is formed of a hub having left and right halves with a wing extending transversely from each half. The hub defines between these halves a passageway for a catheter, where the passageway has sides defined by opposing wall surfaces of said halves, and top and bottom walls extending between these halves. A funnel is situated at the proximal end of the hub and a sheath is situated at the distal end of the hub. The funnel, hub and sheath have respective lumens which are aligned forming a continuous passageway. The funnel, hub and sheath furthermore have tear lines along their top and bottom surfaces adapting this catheter introducer to be split apart into two halves and discarded after introduction of a catheter therethrough.
    • 用于接收导管的远端的超针剥离护套导管引导器由具有左半部和右半部的轮毂形成,所述轮毂具有从每个半部横向延伸的翼部。 轮毂在这些半部之间限定用于导管的通道,其中通道具有由所述半部的相对的壁表面限定的侧面,以及在这两半之间延伸的顶壁和底壁。 漏斗位于轮毂的近端,护套位于轮毂的远端。 漏斗,轮毂和护套具有对准的相应管腔,形成连续通道。 漏斗,轮毂和护套还具有沿其顶部和底部表面的撕裂线,使得该导管导引器被分裂成两半,并且在导管穿过其后被丢弃。
    • 9. 发明申请
    • 4,5-Disubstituted-2-aminopyrimidines
    • 4,5-二取代-2-氨基嘧啶
    • US20050171134A1
    • 2005-08-04
    • US11090474
    • 2005-03-25
    • Jeremy DavisDavid Festus Moffat
    • Jeremy DavisDavid Festus Moffat
    • A61K31/505A61P9/00A61P9/10A61P9/14A61P17/06A61P27/02A61P29/00A61P35/00A61P43/00C07D239/42C07D401/12C07D403/12C07D521/00A61K31/506C07D43/02
    • C07D239/42A61K31/505C07D231/12C07D233/56C07D249/08C07D401/12C07D403/12
    • Pyrimidines of formla (1) are described: wherein R1 is a —XR6 group; R2 and R3 which may be the same or different is each a hydrogen or halogen atom or a group selected from an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, —OH, —OR10 [where R10 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group) —SH, —NO2, —CN, —SR10, —COR10, S(O)R10, —SO2R8, —SO2N(R8)(R9), —CO2R8, —CON(R8)(R9), —CSN(R8)(R9), —NH2 or substituted amino group; R4 is a X1R11 group where X1 is a covalent bond or a —C(R12)(R13)— [where each of R12 and R13 is a hydrogen or halogen atom or a hydroxyl, alkyl or haloalkyl group] or —C(O)— group and R11 is an optionally substituted phenyl, thienyl, thiazolyl or indolyl group; R5 is a halogen atom or an alkynyl group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis
    • 描述了formla(1)的嘧啶:其中R 1是-XR 6 C 6; R 2和R 3可以相同或不同,各自为氢或卤素原子或选自任选取代的脂族,脂环族,杂脂肪族,杂环脂族, OH,-OR 10 [其中R 10是任选取代的脂族,脂环族,杂脂族,杂脂族,芳族或杂芳族基团)-SH,-NO 2, -CON,-SR 10,-COR 10,S(O)R 10,-SO 2, (R 9),-SO 2 N(R 8), - CO 2, -CON(R 8)(R 9),-CSN(R 8),R 8, (R 9),-NH 2或取代的氨基; R 4是其中X 1是共价键或C(R(R 1))的X 1,R 11, (R 13) - [其中R 12和R 12各自为氢或卤素原子 或羟基,烷基或卤代烷基]或-C(O) - 基,R 11是任选取代的苯基,噻吩基,噻唑基或吲哚基; R 5是卤素原子或炔基; 及其盐,溶剂合物,水合物和N-氧化物。 这些化合物是选择性KDR激酶和/或FGFr激酶抑制剂,并且可用于预防和治疗与血管发生相关的疾病状态